Effect of Tobacco Smoke Exposure on Functional Capacity, Respiratory Muscle Strength, and Physical Activity Level in Patients with Pulmonary Arterial Hypertension: A Preliminary Study

Abstract

Purpose: It is known that tobacco smoke exposure is a risk factor for the development of pulmonary arterial hypertension PAH . In addition, tobacco smoke exposure can cause numerous health problems. This study aimed to compare functional capacity, respiratory muscle strength, and physical activity level between the patients with PAH who have or do not have tobacco smoke exposure. Methods: Seventeen patients with PAH who has tobacco smoke exposure and 20 nonsmoker patients were included in this cross-sectional study. Tobacco smoke exposure was defined as current smokers, ex-smokers, and passive smokers. The study outcomes included the maximal inspiratory and expiratory pressure measurement, 6-minute walk test, and physical activity. Results: There was no significant difference for age, gender, body mass index, pulmonary arterial pressure, and functional class between the two groups p>0.05 . Inspiratory muscle strength p=0.035 , functional exercise capacity p=0.040 and physical activity level p=0.034 were lower in patients with tobacco smoke expose compared to the nonsmokers. Conclusion: The results of this study showed that functional capacity, respiratory muscle strength, and physical activity level were significantly lower in patients with tobacco smoke expose than the nonsmoker patients with PAH. These findings suggest that tobacco smoking is not only associated with PAH risk but also numerous health problems, specifically important ones for this population

Keywords

• pulmonary arterial hypertension, smoking, cigarette, exercise, rehabilitation

References

1. 1. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019;53:1801913. [CrossRef]
2. 2. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2012;122:4306–4313. [CrossRef]
3. 3. Schiess R, Senn O, Fischler M, et al. Tobacco smoke: a risk factor for pulmonary arterial hypertension? A case-control study. Chest 2010;138:1086–1092. [CrossRef]
4. 4. Gibbs K, Collaco JM, McGrath-Morrow SA. Impact of Tobacco Smoke and Nicotine Exposure on Lung Development. Chest 2016;149:552– 561. [CrossRef]
5. 5. Wright JL, Tai H, Churg A. Cigarette smoke induces persisting increases of vasoactive mediators in pulmonary arteries. Am J Respir Cell Mol Biol 2004;31:501–509. [CrossRef]
6. 6. Barberà JA, Peinado VI, Santos S, Ramirez J, Roca J, Rodriguez-Roisin R. Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers. Am J Respir Crit Care Med 2001;164:709–713. [CrossRef]
7. 7. Wright JL, Zhou S, Churg A. Pulmonary hypertension and vascular oxidative damage in cigarette smoke exposed eNOS(-/-) mice and human smokers. Inhal Toxicol 2012;24:732–740. [CrossRef]
8. 8. Naser H, Hadi N, Ibrahim A, Assad A. Study the Pulmonary Hypertension among Heavy Smokers Young Adult Males before the Clinical Evidences of Chronic Lung Disease. J Clin Exp Cardiolog 2017;8:2. [CrossRef]

9. 9. Ling Y, Johnson MK, Kiely DG, et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 2012;186:790–796. [CrossRef]
10. 10. Keusch S, Hildenbrand FF, Bollmann T, et al. Tobacco smoke exposure in pulmonary arterial and thromboembolic pulmonary hypertension. Respiration 2014;88:38–45. [CrossRef]
11. 11. Furlanetto KC, Mantoani LC, Bisca G, et al. Reduction of physical activity in daily life and its determinants in smokers without airflow obstruction. Respirology 2014;19:369–375. [CrossRef]
12. 12. Moslemi-Haghighi F, Rezaei I, Ghaffarinejad F, Lari R, Pouya F. Comparison of Physical Fitness among Smoker and Non-Smoker Men. Addict Health 2011;3:15–19. https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3905518/
13. 13. Ibrahim AA. Impact of smoking on aerobic capacity in young adult smokers. Int J Med Res Health Sci 2016;5:26–30. https://www.ijmrhs. com/medical-research/impact-of-smoking-on-aerobic-capacity-inyoung-adult-smokers.pdf
14. 14. Caram LMO, Ferrari R, Bertani AL, et al. Smoking and Early COPD as Independent Predictors of Body Composition, Exercise Capacity, and Health Status. PLoS One 2016;11:e0164290. [CrossRef]
15. 15. Tran DL, Lau EM, Celermajer DS, Davis GM, Cordina R. Pathophysiology of exercise intolerance in pulmonary arterial hypertension. Respirology 2018;23:148–159. [CrossRef]
16. 16. Black LF, Hyatt RE. Maximal respiratory pressures: normal values and relationship to age and sex. Am Rev Respir Dis 1969;99:696–702. https://pubmed.ncbi.nlm.nih.gov/5772056/
17. 17. American Thoracic Society (ATS) statement: guidelines for the sixminute walk test. Am J Respir Crit Care Med 2002;166:111–117. [CrossRef]
18. 18. Saglam M, Arikan H, Savci S, et al. International physical activity questionnaire: reliability and validity of the Turkish version. Percept Mot Skills 2010;111:278–284. [CrossRef]
19. 19. Craig CL, Marshall AL, Sjostrom M, et al. International physical activity questionnaire:12-country reliability and validity. Med Sci Sports Exerc 2003;35:1381–1395. [CrossRef]
20. 20. Cohen J. Statistical power analysis for the behavioral sciences, 2nd ed. NJ, USA: Erbaum Press, Hillsdale; 1988. http://www.utstat.toronto. edu/~brunner/oldclass/378f16/readings/CohenPower.pdf
21. 21. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT; Lancet Physical Activity Series Working Group. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 2012;380:219–229. [CrossRef]
22. 22. Elbehairy AF, Guenette JA, Faisal A, et al. Mechanisms of exertional dyspnoea in symptomatic smokers without COPD. Eur Respir J 2016;48:694–705. [CrossRef]
23. 23. Woodruff PG, Barr RG, Bleecker E, et al. Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. N Engl J Med 2016;374:1811–1821. [CrossRef]
24. 24. Mesquita R, Gonçalves CG, Hayashi D, et al. Smoking status and its relationship with exercise capacity, physical activity in daily life and quality of life in physically independent, elderly individuals. Physiotherapy 2015;101:55–61. [CrossRef]
25. 25. Muller PT, Barbosa GW, O’Donnell DE, Neder JA. Cardiopulmonary and Muscular Interactions: Potential Implications for Exercise (In) tolerance in Symptomatic Smokers Without Chronic Obstructive Pulmonary Disease. Front Physiol 2019;10:859. [CrossRef]
26. 26. Barn P, Giles L, Héroux ME, Kosatsky T. A review of the experimental evidence on the toxicokinetics of carbon monoxide: the potential role of pathophysiology among susceptible groups. Environ Health 2018;17:13. [CrossRef]
27. 27. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a populationbased cohort study. Am J Respir Crit Care Med 2007;175:458–463. [CrossRef]
28. 28. Bostanci Ö, Mayda H, Yılmaz C, Kabadayı M, Yılmaz AK, Özdal M. Inspiratory muscle training improves pulmonary functions and respiratory muscle strength in healthy male smokers. Respir Physiol Neurobiol 2019;264:28–32. [CrossRef]
29. 29. Formiga MF, Campos MA, Cahalin LP. Inspiratory Muscle Performance of Former Smokers and Nonsmokers Using the Test of Incremental Respiratory Endurance. Respir Care 2018;63:86–91. [CrossRef]
30. 30. Enright PL, Kronmal RA, Manolio TA, Schenker MB, Hyatt RE. Respiratory muscle strength in the elderly. Correlates and reference values. Cardiovascular Health Study Research Group. Am J Respir Crit Care Med 1994;149:430–438. [CrossRef]